

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Melodiol Global Health Limited
<b>ABN</b>	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	William Lay
<b>Date of last notice</b>	3 February 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Noble House Consulting Ltd - a director-related entity.
<b>Date of change</b>	30 June 2023
<b>No. of securities held prior to change</b>	12,500,000 Fully Paid Ordinary Shares 1,666,667 ME1O Options (\$0.25, 2/11/2024) 10,000,000 ME1OPT41 Options (\$0.18, 6/09/2024) 10,000,000 ME1OPT42 Options (\$0.25, 6/09/2024) 2,500,000 ME1OD Options (\$0.08, 31/01/2027) 10,000,000 ME1PERR43 Performance Rights
<b>Class</b>	ME1OPT56 Options (\$0.20, 17/01/2024) ME1PERR51 Performance Rights
<b>Number acquired</b>	10,000,000 ME1OPT56 Options (\$0.20, 17/01/2024) 7,500,000 ME1PERR51 Performance Rights
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>Issued as part of Mr Lay's remuneration package.</p> <p>Please refer to Resolution 15 of the Notice of Meeting released on ASX on 1 May 2023 for further information.</p>
<b>No. of securities held after change</b>	<p>12,500,000 Fully Paid Ordinary Shares  1,666,667 ME1O Options (\$0.25, 2/11/2024)  10,000,000 ME1OPT41 Options (\$0.18, 6/09/2024)  10,000,000 ME1OPT42 Options (\$0.25, 6/09/2024)  2,500,000 ME1OD Options (\$0.08, 31/01/2027)  10,000,000 ME1OPT56 Options (\$0.20, 17/01/2024)  10,000,000 ME1PERR43 Performance Rights  7,500,000 ME1PERR51 Performance Rights</p>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<p>Options and Performance Rights issued as part of Mr Lay's remuneration package.</p> <p>Please refer to Resolution 15 of the Notice of Meeting released on ASX on 1 May 2023 for further information.</p>

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Melodiol Global Health Limited
<b>ABN</b>	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Benjamin Quirin
<b>Date of last notice</b>	14 October 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	BKAH Pty Ltd as trustee for Quirin Alleaume Trust – of which Mr Quirin is a beneficiary
<b>Date of change</b>	30 June 2023
<b>No. of securities held prior to change</b>	Nil
<b>Class</b>	ME1OPT55 Options (\$0.04, 10/10/2024)
<b>Number acquired</b>	2,000,000 ME1OPT55 Options (\$0.04, 10/10/2024)
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Issued as part of Mr Quirin's remuneration package.  Please refer to Resolution 8 of the Notice of Meeting released on ASX on 1 May 2023 for further information.
<b>No. of securities held after change</b>	2,000,000 ME1OPT55 Options (\$0.04, 10/10/2024)

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Options issued as part of Mr Quirin's remuneration package.</p> <p>Please refer to Resolution 8 of the Notice of Meeting released on ASX on 1 May 2023 for further information.</p>
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.